Sciwind Biosciences diabetes drug approved in China - OPERA JRNL

ShowBiz & Sports Celebs Lifestyle

Hot

Friday, January 30, 2026

Sciwind Biosciences diabetes drug approved in China

New Photo - Sciwind Biosciences diabetes drug approved in China

Sciwind Biosciences diabetes drug approved in China ReutersJanuary 30, 2026 at 12:50 AM 0 A Sciwind sign is displayed outside the office of Sciwind Biosciences in Hangzhou, Zhejiang province, China July 18, 2025. REUTERS/Andrew Silver SHANGHAI, Jan 30 (Reuters) Sciwind Biosciences' type 2 diabetes treatment Xianyida was approved for use ​in China, the company said on Friday, ‌adding another participant to a hot sector in the world's ‌secondlargest pharmaceutical market.

- - Sciwind Biosciences diabetes drug approved in China

ReutersJanuary 30, 2026 at 12:50 AM

0

A Sciwind sign is displayed outside the office of Sciwind Biosciences in Hangzhou, Zhejiang province, China July 18, 2025. REUTERS/Andrew Silver

SHANGHAI, Jan 30 (Reuters) - Sciwind Biosciences' type 2 diabetes treatment Xianyida was approved for use ​in China, the company said on Friday, ‌adding another participant to a hot sector in the world's ‌second-largest pharmaceutical market.

China has the highest number of adults with diabetes in the world, according to estimates from the International Diabetes Federation, and drugmakers including ⁠Novo Nordisk, Eli ‌Lilly and Innovent Biologics have launched injectable medicines that are designed to support ‍them.

Hangzhou, China-based Sciwind's injection, which is also known by the name ecnoglutide, belongs to a class of drugs ​called GLP-1 receptor agonists, which work by helping ‌control blood sugar levels while triggering a feeling of fullness.

Sciwind has sought to license ecnoglutide abroad and also applied to sell it in China for weight management. Its CEO, Pan Hai, previously ⁠told Reuters that pricing in ​China would be in line ​with other approved competitors.

Unlike Novo's Ozempic and Lilly's Mounjaro, ecnoglutide will not be covered ‍under China's ⁠state-run health insurance scheme for type 2 diabetes treatment. Pan declined to comment on when ⁠it would launch, pricing and whether it would enter the ‌scheme in the future.

(Reporting by Andrew Silver; ‌Editing by Thomas Derpinghaus)

Original Article on Source

Source: "AOL Breaking"

Read More


Source: Breaking

Published: January 30, 2026 at 02:54AM on Source: OPERA MAG

#ShowBiz#Sports#Celebrities#Lifestyle